American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

ANAPTYSBIO, INC (ANAB)

$48.73 +1.31% NASDAQ: ANAB · 15-min delayed

SAN DIEGO, California
Public · NASDAQ: ANAB
104 employees

Visit website Follow

$1.6BMarket cap

$234.6MRevenue · FY2025

-$13.2MNet income

104Employees

ANABNASDAQ

2017IPO

About ANAPTYSBIO, INC

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: ANAB
Employees: 104
IPO date: Jan 26, 2017
Headquarters: 10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, California 92121
Phone: 858-362-6295
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 529900HH4WQT03IG1A12

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: ANAB Nasdaq
SEC CIK: 1370053
LEI: 529900HH4WQT03IG1A12
EIN: 203828755
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Anaptysbio, Inc’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/anaptysbio-inc/"><img src="https://americancompanies.com/badge/anaptysbio-inc.svg" alt="Anaptysbio, Inc — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow ANAPTYSBIO, INC and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $234.6M
Net income: -$13.2M
Total assets: $364.4M
Market cap: $1.6B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: ANAB

$48.73 +1.31%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$20.95 $70.22

52-week range

Market cap: $1.6B
Shares outstanding: 32.9M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jan 26, 2017

Anaptysbio, Inc (ANAB) Stock Price

Reported a net loss of $13.2M in FY2025.
Trading 31% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review ANAPTYSBIO, INC.

Write a review

Newsroom

News about ANAPTYSBIO, INC

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer GlobeNewswire Inc. · 2026-10-19 · positive AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates Zacks Investment Research · 2026-09-21 · negative Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim GlobeNewswire Inc. · 2026-04-24 · positive Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary GlobeNewswire Inc. · 2026-01-08 · neutral GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties Benzinga · 2025-11-21 · negative Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary GlobeNewswire Inc. · 2025-11-21 · neutral

News & sentiment via Polygon.io

FAQ

Anaptysbio, Inc: frequently asked questions

Is Anaptysbio, Inc an American company?

Anaptysbio, Inc is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Anaptysbio, Inc headquartered?

Anaptysbio, Inc is headquartered in San Diego, California, United States.

Is Anaptysbio, Inc publicly traded?

Yes — Anaptysbio, Inc is a publicly traded company. Its stock trades under the ticker symbol ANAB on the NASDAQ.

What does Anaptysbio, Inc do?

Anaptysbio, Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore